RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 11.29

Change

-0.25 (-2.17)%

Market Cap

N/A

Volume

5.60K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-30 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

N/A

USD 1.42B
PSQ ProShares Short QQQ

+0.01 (+0.03%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

-0.07 (-0.30%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

-0.46 (-2.38%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

+0.02 (+0.05%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

-0.42 (-0.78%)

USD 0.23B
RWM ProShares Short Russell2000

+0.14 (+0.67%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

+0.03 (+0.26%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

N/A

USD 0.18B
DOG ProShares Short Dow30

-0.07 (-0.25%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.13% 40% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.13% 40% F 38% F
Trailing 12 Months  
Capital Gain -0.62% 88% B+ 41% F
Dividend Return 2.57% 64% D 47% F
Total Return 1.95% 88% B+ 38% F
Trailing 5 Years  
Capital Gain -61.73% 78% C+ 6% D-
Dividend Return 2.97% 75% C 6% D-
Total Return -58.76% 78% C+ 5% F
Average Annual (5 Year Horizon)  
Capital Gain 66.64% 39% F 96% N/A
Dividend Return 68.09% 39% F 96% N/A
Total Return 1.45% 62% D 35% F
Risk Return Profile  
Volatility (Standard Deviation) 433.01% 63% D 3% F
Risk Adjusted Return 15.72% 52% F 33% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.